Physician profile
Judy Cheng
NPI 1154707693
$4,058.76
in general payments reported to CMS, 2019-2025
22 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $44.69 · 2022: $404 · 2023: $739 · 2024: $854 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $607.84 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $509.39 | 2024-2025 | |
| Allergan, INC. | $429.51 | 2019 | |
| Celgene Corporation | $260.77 | 2019 | |
| Abbvie INC. | $256.74 | 2023-2025 | Skyrizi, Botox |
| Janssen Biotech, INC. | $220.17 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $216.16 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $208.12 | 2019-2025 | Oracea, Nemluvio |
| Novartis Pharmaceuticals Corporation | $200.59 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $188.50 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $160.12 | 2022-2023 | Taltz |
| Organon LLC | $152.84 | 2025 | Vtama |
| Genzyme Corporation | $137.31 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $134.68 | 2019-2022 | |
| Almirall LLC | $118.94 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $50.00 | 2022 | |
| Amgen INC. | $49.05 | 2023-2024 | Otezla |
| Pfizer INC. | $47.77 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.81 | 2024 | Spevigo |
| Dermavant Sciences, INC. | $25.45 | 2024 | Vtama |
| Genentech USA, INC. | $15.84 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.